Physician profile
Timothy C Bryan
NPI 1831133743
$6,883.56
in general payments reported to CMS, 2019-2025
44 companies · $598 in 2025
The $598 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $738 · 2020: $730 · 2021: $1,160 · 2022: $946 · 2023: $955 · 2024: $1,756 · 2025: $598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,289 · Entertainment: $19.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.23 |
| Entertainment | $19.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $1,714.40 | 2024-2025 | Excelsius3d Imaging System, Elsa, Excelsius Gps |
| Abbvie INC. | $730.74 | 2021-2024 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $690.30 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $616.52 | 2019-2024 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $525.84 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $321.78 | 2020-2024 | Mounjaro, Jardiance |
| Abbott Laboratories | $258.89 | 2019-2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Lucid Diagnostics INC. | $221.45 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $207.48 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $144.20 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $132.25 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $128.88 | 2019-2020 | |
| Allergan, INC. | $96.71 | 2019-2021 | |
| Optinose US, INC. | $80.34 | 2021-2022 | |
| Amgen INC. | $76.77 | 2021-2024 | Repatha, Otezla |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.